Today's Trend
Janux Therapeutics, Inc. (NASDAQ: JANX) stock appears to be supported today by a wave of mostly positive analyst commentary, even as a small insider sale adds a bit of caution. The shares have edged higher recently as investors weigh improved earnings estimates against the company’s ongoing losses.
- Wedbush reaffirmed a Buy rating on Janux Therapeutics, which helps reinforce bullish sentiment around the stock. Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
- HC Wainwright raised earnings estimates across several future periods, including 2026 through 2029, suggesting improving expectations for Janux Therapeutics’ financial outlook.
- The analyst also increased near-term EPS forecasts for Q2, Q3, and Q4 2026, which can be interpreted as a sign that operating trends may be improving.
- Vice President Maria Dobek sold 2,038 shares at an average price of $14.17, a modest insider transaction that may be viewed as a small overhang but not necessarily a major red flag. SEC Form 4 filing
- Janux remains unprofitable, and even the upgraded forecasts still point to losses, which keeps the long-term risk profile elevated.
Bottom line: JANX is moving on analyst optimism, especially upgraded earnings estimates and a maintained Buy rating. The insider sale is a mild negative, but the dominant news flow is constructive for the stock.